Skip to content

RGB-19 Phase I Clinical Study

RGB-19 Phase I Clinical Study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2031230029
Enrollment
110
Registered
2023-04-16
Start date
2023-04-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Participants

Interventions

RGB-19 injection or Tocilizumab injection

Sponsors

Karibe Yusuke
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Male volunteers who voluntarily wish to participate in the study, have the capacity to provide consent, and have provided written informed consent to participate in the study. Volunteers from 20 to 40 years of age (both inclusive) when signing informed consent.

Exclusion criteria

Exclusion criteria: Volunteers previously exposed to tocilizumab, any other IL-6 inhibitors, or IL-6 receptor inhibitors.

Design outcomes

Primary

MeasureTime frame
Maximum serum drug concentration (Cmax) AUC from 0 hours (immediately before administration) to infinity (AUCinf)

Contacts

Public ContactPublic relations

Mochida Pharmaceutical Co., Ltd.

webmaster@mochida.co.jp+81-3-3225-6303

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026